Newpath Partners is a venture capital fund founded and managed by physician-scientist Tom Cahill, MD, PhD, who serves on boards of multiple biotech companies and focuses on forming new companies "from the ground up" around academic discoveries rather than backing already-formed startups. The fund specializes in breakthrough biology platforms like gene editing and regenerative medicine, managing ~$350M with a lean team that has achieved an unusually high rate of company formation and exits per investment professional compared to typical life-science VCs.